15 articles
Average Ozempic-strength semaglutide weight loss in the STEP trials is about 14-15% of body weight over 68 weeks, with about half reaching 15%+ and a third reaching 20%+. Here is the full evidence-based picture, with timeline, individual variability, and how it stacks up against Mounjaro.
In the first randomized trial of semaglutide for alcohol use disorder, low-dose semaglutide cut lab-measured alcohol consumption by a medium-to-large effect size (P = .01) and reduced craving on the Penn Alcohol Craving Scale (P = .01) over 9 weeks. Here's what the clinical evidence — and what it doesn't — says about drinking on a GLP-1.
Semaglutide causes constipation in 23–39% of weight-loss-trial patients (vs 9–11% on placebo) by slowing gastric emptying about 36 minutes and cutting food and fluid intake. Most cases respond to hydration, fiber, walking, and an osmotic laxative — without stopping the drug.
Semaglutide takes off 10–14% of pre-treatment lean body mass over 68 weeks — about 6 kg in absolute terms. Body composition still improves because fat shrinks faster, and resistance training preserves ~93.5% of the muscle that would otherwise be lost. Evidence from STEP 1 DXA substudy and 2024 reviews in Diabetes Care and Diabetes Obes Metab.
Ozempic's four dose steps (0.25 → 0.5 → 1.0 → 2.0 mg) and the four-week wait between them are fixed by semaglutide's one-week half-life. Here's the full schedule, missed-dose rules, and what to do after a supply gap — sourced from STEP 1, STEP 4, and the FDA label.
Semaglutide (Ozempic, Wegovy) vs tirzepatide (Mounjaro, Zepbound) — what the SURMOUNT-5 head-to-head trial, SURPASS-2, real-world data, and cardiovascular outcomes evidence actually show about semaglutide vs tirzepatide for weight loss, glucose control, and side effects.
Medicare covers Ozempic for type 2 diabetes but not for weight loss. Here's what the 2026 Part D rules mean for seniors, and how the July 2026 GLP-1 Bridge will change coverage for Wegovy and Zepbound.
What 4-5 years of randomized and real-world data actually show about long-term Ozempic/semaglutide use: cardiovascular protection, kidney outcomes, thyroid risk reassessment, muscle-mass trajectory, and weight regain after discontinuation.
Yes — insurance evaluates the prescription, not where it was prescribed. Here is how telehealth and insurance work together for Ozempic.
Ozempic is FDA-approved for diabetes, not weight loss — so most insurers deny it for weight management. Here are your options.
A comprehensive guide to what you'll actually pay for Ozempic, Wegovy, Mounjaro, and Zepbound with insurance, Medicare, Medicaid, and self-pay options. Pricing verified April 2026.
A 2025 cohort of 1+ million matched patients found GLP-1 users had 40% higher odds of hair loss at 12 months — mostly reversible telogen effluvium triggered by rapid weight loss. Here's what the research actually shows.
Nausea affects 20–40% of GLP-1 users but is mostly mild, peaks during dose escalation, and fades within weeks. Here's what 8 clinical studies and thousands of real users reveal about why it happens and how to manage it.
You need 1.2–1.6g of protein per kg of body weight daily on a GLP-1 medication. Here's what 261 clinical studies and 2,000+ real users reveal about protein targets and muscle preservation.
No articles in this category yet.